Clarity Pharmaceuticals (ASX:CU6) Buyback Yield %: -28.58 (As of Jul. 02, 2026)


ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
39 GF Score
Price A$2.15
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Buyback Yield %?

Clarity Pharmaceuticals ASX:CU6 +1.42% 39 Buyback Yield % is -28.58 as of Jul. 02, 2026. GuruFocus rates ASX:CU6 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review. Among 745 Biotechnology companies, Clarity Pharmaceuticals ranks worse than 75.57% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Clarity Pharmaceuticals's current buyback yield was -28.58%.

Clarity Pharmaceuticals Buyback Yield % Related Terms

Clarity Pharmaceuticals Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Buyback Yield % Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Buyback Yield %
-65.98 -0.18 -6.82 -0.28

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -6.82 -8.73 -0.28 -15.38

ASX:CU6 vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Clarity Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarity Pharmaceuticals Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Buyback Yield % falls into.


ASX:CU6
39GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Clarity Pharmaceuticals's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.193 + 2.405) / 803.68
=-0.28%

Clarity Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-10.768 + 204.215) / 1257.4614
=-15.38%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -28.58 mean?
Clarity Pharmaceuticals (ASX:CU6) has a Buyback Yield % of -28.58 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Clarity Pharmaceuticals and its competitors. According to the industry distribution chart, Clarity Pharmaceuticals ranks #563 out of 745 companies in the Biotechnology industry, placing it in the top 75.6%.
Is Clarity Pharmaceuticals' Buyback Yield % too high?
Clarity Pharmaceuticals' current Buyback Yield % is -28.58. Based on the distribution chart, Clarity Pharmaceuticals ranks #563 out of 745 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clarity Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clarity Pharmaceuticals ranks #563 out of 745 companies for Buyback Yield %. This places Clarity Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Buyback Yield % is -28.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Buyback Yield % of -28.58. The current Buyback Yield % is -28.58. Clarity Pharmaceuticals' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Buyback Yield % is -28.58 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
39GF Score

Get the complete analysis for ASX:CU6

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.15
Price